Yasuko Iwakiri, PhD
Research & Publications
Biography
News
Locations
Research Summary
The central focus of my research is the study of liver fibrosis and portal hypertension. Both are major subjects in the study of liver disease. My laboratory also investigates the role of vascular biology in liver disease pathogenesis. Although the pathology of the liver has examined cellular components and functions of the liver, the contribution of the vasculature both inside and outside the liver and related hemodynamic changes have not been well investigated. This is the uniqueness of my research and originated from my study of portal hypertension, which represents a liver and vascular disease.
Extensive Research Description
Vascular biology of the liver:
My lab has been committed to working on the lymphatic system in the liver, which is a very unexplored area in the study of liver biology (Chung & Iwakiri, CMH, 2013; Iwakiri, Hepatology, 2016; Tanaka & Iwakiri, CMGH, 2016).
Liver fibrosis:
- We investigate the role of each major liver cell type in fibrogenesis with a particular interest in hepatic stellate cells (HSC), a cell type that has the most direct impact on the development of fibrosis. We have determined that a protein called Reticulon 4B (a.k.a., Nogo-B) increases fibrosis by promoting collagen production by HSCs (Zhang et al., Hepatology, 2011) and protecting HSCs from apoptosis (Tashiro et al., Am J Pathol, 2013).
- In collaboration with Dr. Mark Saltzman (Yale University), we have explored the therapeutic potential of targeting Reticulon 4B in HSCs for liver fibrosis by delivering siRNA encapsulated in nanoparticles. While nanoparticles have been considered an important tool for delivery of drugs and the liver has been known to retain nanoparticles, their cellular distribution in the liver was not clearly understood. We conducted extensive analyses of liver cell uptake of nanoparticles and demonstrated their cellular distribution in vivo for the first time (Park et al., Nanomedicine, 2016). This study is significant since the effectiveness and safety of medical application of nanoparticles for liver therapy depends on their specific delivery to targeted cell populations.
Kupffer cells/macrophages in the pathogenesis of alcohol-induced liver disease:
Alcohol abuse causes liver disease, whose spectrum includes alcoholic fatty liver, alcoholic hepatitis, fibrosis, cirrhosis and hepatocellular carcinoma in a progressive manner. Early intervention may prevent progression to cirrhosis and hepatocellular carcinoma, but effective treatments are limited due to our incomplete understanding of the molecular and cellular mechanisms of alcohol-induced liver injury. My lab studies the mechanism of alcohol-induced liver injury, in which Kupffer cells (liver resident macrophages) have a pivotal role. We also explore therapeutic potential of nanoparticle delivery to Kupffer cells for the treatment of alcoholic liver disease.
Coauthors
Research Interests
Fibrosis; Hypertension, Portal; Kupffer Cells; Liver Regeneration; Pancreatitis; Splenomegaly; Vascular Diseases; Lymphangiogenesis; Endothelial Cells
Public Health Interests
Cancer; Cardiovascular Diseases
Research Image
Immune cell infiltration to the portal tract of the liver
Selected Publications
- Portal Hypertension in Alcohol-Associated HepatitisMcConnell M, Iwakiri Y. Portal Hypertension in Alcohol-Associated Hepatitis. Current Hepatology Reports 2023, 22: 67-73. PMID: 37214274, PMCID: PMC10075503, DOI: 10.1007/s11901-023-00601-y.
- Overexpression of NgBR inhibits high-fat diet–induced atherosclerosis in ApoE-deficiency miceGong K, Wang M, Wang D, Gao Y, Ma L, Yang X, Zhu X, Chen S, Zhang M, Li H, Chen Y, Hu W, Miao Q, Iwakiri Y, Liao C, Duan Y, Han J. Overexpression of NgBR inhibits high-fat diet–induced atherosclerosis in ApoE-deficiency mice. Hepatology Communications 2023, 7: e0048. PMID: 36996002, PMCID: PMC10069848, DOI: 10.1097/hc9.0000000000000048.
- Lymphatics in the liver for translational scienceIwakiri Y. Lymphatics in the liver for translational science. Clinical Liver Disease 2023, 21: 122-124. DOI: 10.1097/cld.0000000000000019.
- The evolving role of liver sinusoidal endothelial cells in liver health and diseaseMcConnell M, Kostallari E, Ibrahim S, Iwakiri Y. The evolving role of liver sinusoidal endothelial cells in liver health and disease. Hepatology 2023, 78: 649-669. PMID: 36626620, PMCID: PMC10315420, DOI: 10.1097/hep.0000000000000207.
- Obituary for Roberto J. Groszmann—The Father of Portal HypertensionShah V, Iwakiri Y, Boyer J. Obituary for Roberto J. Groszmann—The Father of Portal Hypertension. Hepatology 2021, 74: 1724-1726. DOI: 10.1002/hep.31996.
- Reduced Nogo expression inhibits diet-induced metabolic disorders by regulating ChREBP and insulin activityZhang S, Guo F, Yu M, Yang X, Yao Z, Li Q, Wei Z, Feng K, Zeng P, Zhao D, Li X, Zhu Y, Miao QR, Iwakiri Y, Chen Y, Han J, Duan Y. Reduced Nogo expression inhibits diet-induced metabolic disorders by regulating ChREBP and insulin activity. Journal Of Hepatology 2020, 73: 1482-1495. PMID: 32738448, DOI: 10.1016/j.jhep.2020.07.034.
- Endothelial Leukocyte Cell–Derived Chemotaxin 2/Tyrosine Kinase With Immunoglobulin‐Like and Epidermal Growth Factor–Like Domains 1 Signaling in Liver FibrosisSu T, Iwakiri Y. Endothelial Leukocyte Cell–Derived Chemotaxin 2/Tyrosine Kinase With Immunoglobulin‐Like and Epidermal Growth Factor–Like Domains 1 Signaling in Liver Fibrosis. Hepatology 2020, 72: 347-349. PMID: 32060947, DOI: 10.1002/hep.31183.
- Pathophysiology of Portal HypertensionIwakiri Y, Groszmann R. Pathophysiology of Portal Hypertension. 2020, 659-669. DOI: 10.1002/9781119436812.ch51.
- O-GlcNAc transferase suppresses necroptosis and liver fibrosisZhang B, Li MD, Yin R, Liu Y, Yang Y, Mitchell-Richards KA, Nam JH, Li R, Wang L, Iwakiri Y, Chung D, Robert ME, Ehrlich BE, Bennett AM, Yu J, Nathanson MH, Yang X. O-GlcNAc transferase suppresses necroptosis and liver fibrosis. JCI Insight 2019, 4: e127709. PMID: 31672932, PMCID: PMC6948774, DOI: 10.1172/jci.insight.127709.
- Digoxin improves steatohepatitis with differential involvement of liver cell subsets in mice through inhibition of PKM2 transactivationZhao P, Han SN, Arumugam S, Yousaf MN, Qin Y, Jiang JX, Torok NJ, Chen Y, Mankash MS, Liu J, Li J, Iwakiri Y, Ouyang X. Digoxin improves steatohepatitis with differential involvement of liver cell subsets in mice through inhibition of PKM2 transactivation. AJP Gastrointestinal And Liver Physiology 2019, 317: g387-g397. PMID: 31411894, PMCID: PMC6842989, DOI: 10.1152/ajpgi.00054.2019.
- Poly(amine-co-ester) nanoparticles for effective Nogo-B knockdown in the liverCui J, Piotrowski-Daspit AS, Zhang J, Shao M, Bracaglia LG, Utsumi T, Seo YE, DiRito J, Song E, Wu C, Inada A, Tietjen GT, Pober JS, Iwakiri Y, Saltzman WM. Poly(amine-co-ester) nanoparticles for effective Nogo-B knockdown in the liver. Journal Of Controlled Release 2019, 304: 259-267. PMID: 31054286, PMCID: PMC6613984, DOI: 10.1016/j.jconrel.2019.04.044.
- Integrated analysis of microRNA and mRNA expression profiles in splenomegaly induced by non-cirrhotic portal hypertension in ratsSaruwatari J, Dong C, Utsumi T, Tanaka M, McConnell M, Iwakiri Y. Integrated analysis of microRNA and mRNA expression profiles in splenomegaly induced by non-cirrhotic portal hypertension in rats. Scientific Reports 2018, 8: 17983. PMID: 30573742, PMCID: PMC6301948, DOI: 10.1038/s41598-018-36297-0.
- Lymphatics in the liverTanaka M, Iwakiri Y. Lymphatics in the liver. Current Opinion In Immunology 2018, 53: 137-142. PMID: 29772409, PMCID: PMC6986420, DOI: 10.1016/j.coi.2018.04.028.
- Is miR‐21 a potent target for liver fibrosis?Lai S, Iwakiri Y. Is miR‐21 a potent target for liver fibrosis? Hepatology 2018, 67: 2082-2084. PMID: 29315674, PMCID: PMC5992001, DOI: 10.1002/hep.29774.
- Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actionsMinayoshi Y, Maeda H, Yanagisawa H, Hamasaki K, Mizuta Y, Nishida K, Kinoshita R, Enoki Y, Imafuku T, Chuang VTG, Koga T, Fujiwara Y, Takeya M, Sonoda K, Wakayama T, Taguchi K, Ishima Y, Ishida T, Iwakiri Y, Tanaka M, Sasaki Y, Watanabe H, Otagiri M, Maruyama T. Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions. Drug Delivery 2018, 25: 1055-1065. PMID: 29688069, PMCID: PMC6058604, DOI: 10.1080/10717544.2018.1464083.
- Novel application and serial evaluation of tissue-engineered portal vein grafts in a murine modelMaxfield MW, Stacy MR, Kurobe H, Tara S, Yi T, Cleary MA, Zhuang ZW, Rodriguez-Davalos MI, Emre SH, Iwakiri Y, Shinoka T, Breuer CK. Novel application and serial evaluation of tissue-engineered portal vein grafts in a murine model. Regenerative Medicine 2017, 12: 929-938. PMID: 29215317, PMCID: PMC5827823, DOI: 10.2217/rme-2017-0021.
- Corrigendum to “Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension” [J Hepatol 62 (2015) 325–331]Mookerjee RP, Mehta G, Balasubramaniyan V, Mohamed FEZ, Davies N, Sharma V, Iwakiri Y, Jalan R. Corrigendum to “Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension” [J Hepatol 62 (2015) 325–331]. Journal Of Hepatology 2017, 67: 1124. PMID: 28893453, DOI: 10.1016/j.jhep.2017.08.004.
- Biology of portal hypertensionMcConnell M, Iwakiri Y. Biology of portal hypertension. Hepatology International 2017, 12: 11-23. PMID: 29075990, PMCID: PMC7090883, DOI: 10.1007/s12072-017-9826-x.
- The portal hypertension syndrome: etiology, classification, relevance, and animal modelsBosch J, Iwakiri Y. The portal hypertension syndrome: etiology, classification, relevance, and animal models. Hepatology International 2017, 12: 1-10. PMID: 29064029, DOI: 10.1007/s12072-017-9827-9.
- ReplyPark JK, Iwakiri Y. Reply. Hepatology 2017, 66: 1702-1703. PMID: 28745830, DOI: 10.1002/hep.29404.
- Comparative efficacy and safety of antibody induction therapy for the treatment of kidney: a network meta-analysisShao M, Tian T, Zhu X, Ming Y, Iwakiri Y, Ye S, Ye Q. Comparative efficacy and safety of antibody induction therapy for the treatment of kidney: a network meta-analysis. Oncotarget 2017, 5: 66426-66437. PMID: 29029524, PMCID: PMC5630424, DOI: 10.18632/oncotarget.19815.
- ReplyIwakiri Y. Reply. Hepatology 2017, 65: 2134-2134. PMID: 28195342, DOI: 10.1002/hep.29102.
- Alcohol and calcium make a potent cocktailIwakiri Y, Nathanson MH. Alcohol and calcium make a potent cocktail. The Journal Of Physiology 2017, 595: 3109-3110. PMID: 28295353, PMCID: PMC5430223, DOI: 10.1113/jp274133.
- An endoplasmic reticulum protein, Nogo‐B, facilitates alcoholic liver disease through regulation of kupffer cell polarizationPark J, Shao M, Kim MY, Baik SK, Cho MY, Utsumi T, Satoh A, Ouyang X, Chung C, Iwakiri Y. An endoplasmic reticulum protein, Nogo‐B, facilitates alcoholic liver disease through regulation of kupffer cell polarization. Hepatology 2017, 65: 1720-1734. PMID: 28090670, PMCID: PMC5397326, DOI: 10.1002/hep.29051.
- The Hepatic Lymphatic Vascular System: Structure, Function, Markers, and LymphangiogenesisTanaka M, Iwakiri Y. The Hepatic Lymphatic Vascular System: Structure, Function, Markers, and Lymphangiogenesis. Cellular And Molecular Gastroenterology And Hepatology 2016, 2: 733-749. PMID: 28105461, PMCID: PMC5240041, DOI: 10.1016/j.jcmgh.2016.09.002.
- The lymphatic system: A new frontier in hepatologyIwakiri Y. The lymphatic system: A new frontier in hepatology. Hepatology 2016, 64: 706-707. PMID: 27228259, PMCID: PMC4992465, DOI: 10.1002/hep.28650.
- Cellular distribution of injected PLGA-nanoparticles in the liverPark JK, Utsumi T, Seo YE, Deng Y, Satoh A, Saltzman WM, Iwakiri Y. Cellular distribution of injected PLGA-nanoparticles in the liver. Nanomedicine Nanotechnology Biology And Medicine 2016, 12: 1365-1374. PMID: 26961463, PMCID: PMC4889500, DOI: 10.1016/j.nano.2016.01.013.
- Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthaseIwakiri Y. Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthase. Clinical And Molecular Hepatology 2015, 21: 319-325. PMID: 26770919, PMCID: PMC4712158, DOI: 10.3350/cmh.2015.21.4.319.
- Pigment Epithelium-Derived Factor (PEDF) Inhibits Wnt/β-catenin Signaling in the LiverProtiva P, Gong J, Sreekumar B, Torres R, Zhang X, Belinsky GS, Cornwell M, Crawford SE, Iwakiri Y, Chung C. Pigment Epithelium-Derived Factor (PEDF) Inhibits Wnt/β-catenin Signaling in the Liver. Cellular And Molecular Gastroenterology And Hepatology 2015, 1: 535-549.e14. PMID: 26473164, PMCID: PMC4604042, DOI: 10.1016/j.jcmgh.2015.06.006.
- Nitric oxide in liver diseasesIwakiri Y, Kim MY. Nitric oxide in liver diseases. Trends In Pharmacological Sciences 2015, 36: 524-536. PMID: 26027855, PMCID: PMC4532625, DOI: 10.1016/j.tips.2015.05.001.
- Nonalcoholic fatty liver disease induced by noncanonical Wnt and its rescue by Wnt3aWang S, Song K, Srivastava R, Dong C, Go G, Li N, Iwakiri Y, Mani A. Nonalcoholic fatty liver disease induced by noncanonical Wnt and its rescue by Wnt3a. The FASEB Journal 2015, 29: 3436-3445. PMID: 25917329, PMCID: PMC4511193, DOI: 10.1096/fj.15-271171.
- Development of Small Diameter Nanofiber Tissue Engineered Arterial GraftsKurobe H, Maxfield MW, Tara S, Rocco KA, Bagi PS, Yi T, Udelsman B, Zhuang ZW, Cleary M, Iwakiri Y, Breuer CK, Shinoka T. Development of Small Diameter Nanofiber Tissue Engineered Arterial Grafts. PLOS ONE 2015, 10: e0120328. PMID: 25830942, PMCID: PMC4382213, DOI: 10.1371/journal.pone.0120328.
- Can hypersplenism secondary to portal hypertension be treated by non-selective beta blockers?Kim MY, Iwakiri Y. Can hypersplenism secondary to portal hypertension be treated by non-selective beta blockers? Hepatology International 2015, 9: 337-338. PMID: 25788189, PMCID: PMC5046185, DOI: 10.1007/s12072-014-9601-1.
- Hepatic congestion leads to fibrosis: Findings in a newly developed murine modelHidaka H, Iwakiri Y. Hepatic congestion leads to fibrosis: Findings in a newly developed murine model. Hepatology 2015, 61: 428-430. PMID: 25283276, PMCID: PMC4303496, DOI: 10.1002/hep.27550.
- Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertensionMookerjee RP, Mehta G, Balasubramaniyan V, Mohamed Fel Z, Davies N, Sharma V, Iwakiri Y, Jalan R. Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension. Journal Of Hepatology 2014, 62: 325-331. PMID: 25152204, PMCID: PMC4530584, DOI: 10.1016/j.jhep.2014.08.024.
- Vascular pathobiology in chronic liver disease and cirrhosis – Current status and future directionsIwakiri Y, Shah V, Rockey DC. Vascular pathobiology in chronic liver disease and cirrhosis – Current status and future directions. Journal Of Hepatology 2014, 61: 912-924. PMID: 24911462, PMCID: PMC4346093, DOI: 10.1016/j.jhep.2014.05.047.
- eNOS-derived nitric oxide regulates endothelial barrier function through VE-cadherin and Rho GTPasesDi Lorenzo A, Lin M, Murata T, Landskroner-Eiger S, Schleicher M, Kothiya M, Iwakiri Y, Yu J, Huang P, Sessa W. eNOS-derived nitric oxide regulates endothelial barrier function through VE-cadherin and Rho GTPases. Journal Of Cell Science 2014, 127: 2120-2120. PMCID: PMC4074249, DOI: 10.1242/jcs.153601.
- Pathophysiology of Portal HypertensionIwakiri Y. Pathophysiology of Portal Hypertension. Clinics In Liver Disease 2014, 18: 281-291. PMID: 24679494, PMCID: PMC3971388, DOI: 10.1016/j.cld.2013.12.001.
- Reticulon 4 Is Necessary for Endoplasmic Reticulum Tubulation, STIM1-Orai1 Coupling, and Store-operated Calcium EntryJozsef L, Tashiro K, Kuo A, Park EJ, Skoura A, Albinsson S, Rivera-Molina F, Harrison KD, Iwakiri Y, Toomre D, Sessa WC. Reticulon 4 Is Necessary for Endoplasmic Reticulum Tubulation, STIM1-Orai1 Coupling, and Store-operated Calcium Entry. Journal Of Biological Chemistry 2014, 289: 9380-9395. PMID: 24558039, PMCID: PMC3969502, DOI: 10.1074/jbc.m114.548602.
- Pigment Epithelium-Derived Factor (PEDF) Suppresses IL-1β-Mediated c-Jun N-Terminal Kinase (JNK) Activation to Improve Hepatocyte Insulin SignalingGattu AK, Birkenfeld AL, Iwakiri Y, Jay S, Saltzman M, Doll J, Protiva P, Samuel VT, Crawford SE, Chung C. Pigment Epithelium-Derived Factor (PEDF) Suppresses IL-1β-Mediated c-Jun N-Terminal Kinase (JNK) Activation to Improve Hepatocyte Insulin Signaling. Endocrinology 2014, 155: 1373-1385. PMID: 24456163, PMCID: PMC5393334, DOI: 10.1210/en.2013-1785.
- Pathophysiology of Portal HypertensionIwakiri Y, Groszmann R. Pathophysiology of Portal Hypertension. 2014, 3-14. DOI: 10.1007/978-1-4939-0002-2_1.
- Determination of mesenchymal stem cell fate by pigment epithelium‐derived factor (PEDF) results in increased adiposity and reduced bone mineral contentGattu AK, Swenson ES, Iwakiri Y, Samuel VT, Troiano N, Berry R, Church CD, Rodeheffer MS, Carpenter TO, Chung C. Determination of mesenchymal stem cell fate by pigment epithelium‐derived factor (PEDF) results in increased adiposity and reduced bone mineral content. The FASEB Journal 2013, 27: 4384-4394. PMID: 23887690, PMCID: PMC3804749, DOI: 10.1096/fj.13-232900.
- The lymphatic vascular system in liver diseases: its role in ascites formationChung C, Iwakiri Y. The lymphatic vascular system in liver diseases: its role in ascites formation. Clinical And Molecular Hepatology 2013, 19: 99-104. PMID: 23837133, PMCID: PMC3701854, DOI: 10.3350/cmh.2013.19.2.99.
- Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivityBryniarski K, Ptak W, Jayakumar A, Püllmann K, Caplan MJ, Chairoungdua A, Lu J, Adams BD, Sikora E, Nazimek K, Marquez S, Kleinstein SH, Sangwung P, Iwakiri Y, Delgato E, Redegeld F, Blokhuis BR, Wojcikowski J, Daniel AW, Kormelink T, Askenase PW. Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity. Journal Of Allergy And Clinical Immunology 2013, 132: 170-181.e9. PMID: 23727037, PMCID: PMC4176620, DOI: 10.1016/j.jaci.2013.04.048.
- Reticulon 4B (Nogo‐B) facilitates hepatocyte proliferation and liver regeneration in miceGao L, Utsumi T, Tashiro K, Liu B, Zhang D, Swenson ES, Iwakiri Y. Reticulon 4B (Nogo‐B) facilitates hepatocyte proliferation and liver regeneration in mice. Hepatology 2013, 57: 1992-2003. PMID: 23299899, PMCID: PMC3628958, DOI: 10.1002/hep.26235.
- Absence of Nogo-B (Reticulon 4B) Facilitates Hepatic Stellate Cell Apoptosis and Diminishes Hepatic Fibrosis in MiceTashiro K, Satoh A, Utsumi T, Chung C, Iwakiri Y. Absence of Nogo-B (Reticulon 4B) Facilitates Hepatic Stellate Cell Apoptosis and Diminishes Hepatic Fibrosis in Mice. American Journal Of Pathology 2013, 182: 786-795. PMID: 23313137, PMCID: PMC3586693, DOI: 10.1016/j.ajpath.2012.11.032.
- eNOS-derived nitric oxide regulates endothelial barrier function through VE-cadherin and Rho GTPasesDi Lorenzo A, Lin MI, Murata T, Landskroner-Eiger S, Schleicher M, Kothiya M, Iwakiri Y, Yu J, Huang PL, Sessa WC. eNOS-derived nitric oxide regulates endothelial barrier function through VE-cadherin and Rho GTPases. Journal Of Cell Science 2013, 126: 5541-5552. PMID: 24046447, PMCID: PMC3860306, DOI: 10.1242/jcs.115972.
- Transport within the Golgi: for the Study of Glycoprotein MovementSatoh A, Iwakiri Y. Transport within the Golgi: for the Study of Glycoprotein Movement. Trends In Glycoscience And Glycotechnology 2013, 25: 241. DOI: 10.4052/tigg.25.241.
- Activated hepatic stellate cells: Negative regulators of hepatocyte proliferation in liver diseasesChung C, Iwakiri Y. Activated hepatic stellate cells: Negative regulators of hepatocyte proliferation in liver diseases. Hepatology 2012, 56: 389-391. PMID: 22876366, PMCID: PMC3666938, DOI: 10.1002/hep.25761.
- Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressureHuang H, Haq O, Utsumi T, Sethasine S, Abraldes JG, Groszmann RJ, Iwakiri Y. Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure. Journal Of Cellular And Molecular Medicine 2012, 16: 1125-1133. PMID: 21801303, PMCID: PMC3213314, DOI: 10.1111/j.1582-4934.2011.01399.x.
- A role of miR-33 for cell cycle progression and cell proliferationIwakiri Y. A role of miR-33 for cell cycle progression and cell proliferation. Cell Cycle 2012, 11: 1057-1057. PMID: 22395363, DOI: 10.4161/cc.11.6.19744.
- Proteomic Identification of S-Nitrosylated Golgi Proteins: New Insights into Endothelial Cell Regulation by eNOS-Derived NOSangwung P, Greco TM, Wang Y, Ischiropoulos H, Sessa WC, Iwakiri Y. Proteomic Identification of S-Nitrosylated Golgi Proteins: New Insights into Endothelial Cell Regulation by eNOS-Derived NO. PLOS ONE 2012, 7: e31564. PMID: 22363674, PMCID: PMC3283662, DOI: 10.1371/journal.pone.0031564.
- Pigment Epithelium-Derived Factor Regulates Early Pancreatic Fibrotic Responses and Suppresses the Profibrotic Cytokine Thrombospondin-1Schmitz JC, Protiva P, Gattu AK, Utsumi T, Iwakiri Y, Neto AG, Quinn M, Cornwell ML, Fitchev P, Lugea A, Crawford SE, Chung C. Pigment Epithelium-Derived Factor Regulates Early Pancreatic Fibrotic Responses and Suppresses the Profibrotic Cytokine Thrombospondin-1. American Journal Of Pathology 2011, 179: 2990-2999. PMID: 21964188, PMCID: PMC3260804, DOI: 10.1016/j.ajpath.2011.08.009.
- Endothelial dysfunction in the regulation of cirrhosis and portal hypertensionIwakiri Y. Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Liver International 2011, 32: 199-213. PMID: 21745318, PMCID: PMC3676636, DOI: 10.1111/j.1478-3231.2011.02579.x.
- S-nitrosylation of proteins: A new insight into endothelial cell function regulated by eNOS-derived NOIwakiri Y. S-nitrosylation of proteins: A new insight into endothelial cell function regulated by eNOS-derived NO. Nitric Oxide 2011, 25: 95-101. PMID: 21554971, PMCID: PMC3152628, DOI: 10.1016/j.niox.2011.04.014.
- Reticulon 4B (Nogo‐B) is a novel regulator of hepatic fibrosisZhang D, Utsumi T, Huang H, Gao L, Sangwung P, Chung C, Shibao K, Okamoto K, Yamaguchi K, Groszmann RJ, Jozsef L, Hao Z, Sessa WC, Iwakiri Y. Reticulon 4B (Nogo‐B) is a novel regulator of hepatic fibrosis. Hepatology 2011, 53: 1306-1315. PMID: 21480333, PMCID: PMC3667398, DOI: 10.1002/hep.24200.
- The type III inositol 1,4,5-trisphosphate receptor is associated with aggressiveness of colorectal carcinomaShibao K, Fiedler MJ, Nagata J, Minagawa N, Hirata K, Nakayama Y, Iwakiri Y, Nathanson MH, Yamaguchi K. The type III inositol 1,4,5-trisphosphate receptor is associated with aggressiveness of colorectal carcinoma. Cell Calcium 2010, 48: 315-323. PMID: 21075448, PMCID: PMC3572849, DOI: 10.1016/j.ceca.2010.09.005.
- The Systemic and Splanchnic CirculationsIwakiri Y. The Systemic and Splanchnic Circulations. 2010, 305-321. DOI: 10.1007/978-1-60761-866-9_15.
- Vascular biology and pathobiology of the liver: Report of a single‐topic symposiumIwakiri Y, Grisham M, Shah V. Vascular biology and pathobiology of the liver: Report of a single‐topic symposium. Hepatology 2008, 47: 1754-1763. PMID: 18393322, PMCID: PMC2724750, DOI: 10.1002/hep.22203.
- Loss of Akt1 Leads to Severe Atherosclerosis and Occlusive Coronary Artery DiseaseFernández-Hernando C, Ackah E, Yu J, Suárez Y, Murata T, Iwakiri Y, Prendergast J, Miao RQ, Birnbaum MJ, Sessa WC. Loss of Akt1 Leads to Severe Atherosclerosis and Occlusive Coronary Artery Disease. Cell Metabolism 2007, 6: 446-457. PMID: 18054314, PMCID: PMC3621848, DOI: 10.1016/j.cmet.2007.10.007.
- The MoleculesIwakiri Y. The Molecules. Journal Of Clinical Gastroenterology 2007, 41: s288-s294. PMID: 17975478, DOI: 10.1097/mcg.0b013e3181468b4c.
- Decreased intrahepatic response to α1‐adrenergic agonists in lipopolysaccharide‐treated rats is located in the sinusoidal area and depends on Kupffer cell functionLee C, Loureiro‐Silva M, Abraldes JG, Iwakiri Y, Haq O, Groszmann RJ. Decreased intrahepatic response to α1‐adrenergic agonists in lipopolysaccharide‐treated rats is located in the sinusoidal area and depends on Kupffer cell function. Journal Of Gastroenterology And Hepatology 2007, 22: 893-900. PMID: 17498219, DOI: 10.1111/j.1440-1746.2007.04922.x.
- [214] NITRIC OXIDE IS A MEDIATOR OF THE ADENOSINE-INDUCED VASODILATATION OF THE HEPATIC ARTERY IN CCL-CIRRHOTIC RATSZipprich A, Iwakiri Y, Ripoll C, Loureiro-Silva M. [214] NITRIC OXIDE IS A MEDIATOR OF THE ADENOSINE-INDUCED VASODILATATION OF THE HEPATIC ARTERY IN CCL-CIRRHOTIC RATS. Journal Of Hepatology 2007, 46: s89. DOI: 10.1016/s0168-8278(07)61812-1.
- Vascular endothelial dysfunction in cirrhosisIwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. Journal Of Hepatology 2007, 46: 927-934. PMID: 17391799, DOI: 10.1016/j.jhep.2007.02.006.
- Increased neuronal nitric oxide synthase interaction with soluble guanylate cyclase contributes to the splanchnic arterial vasodilation in portal hypertensive ratsKwon SY, Groszmann RJ, Iwakiri Y. Increased neuronal nitric oxide synthase interaction with soluble guanylate cyclase contributes to the splanchnic arterial vasodilation in portal hypertensive rats. Hepatology Research 2007, 37: 58-67. PMID: 17300699, DOI: 10.1111/j.1872-034x.2007.00005.x.
- Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein traffickingIwakiri Y, Satoh A, Chatterjee S, Toomre DK, Chalouni CM, Fulton D, Groszmann RJ, Shah VH, Sessa WC. Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein trafficking. Proceedings Of The National Academy Of Sciences Of The United States Of America 2006, 103: 19777-19782. PMID: 17170139, PMCID: PMC1750883, DOI: 10.1073/pnas.0605907103.
- P013. Nitric oxide synthase establishes a local nitric oxide gradient regulating S-nitrosylation and protein secretionIwakiri Y, Satoh A, Chatterjee S, Shah V, Toomre D, Chalouni C, Fulton D, Groszmann R, Sessa W. P013. Nitric oxide synthase establishes a local nitric oxide gradient regulating S-nitrosylation and protein secretion. Nitric Oxide 2006, 14: 21. DOI: 10.1016/j.niox.2006.04.072.
- Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic stateAbraldes JG, Iwakiri Y, Loureiro-Silva M, Haq O, Sessa WC, Groszmann RJ. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. AJP Gastrointestinal And Liver Physiology 2006, 290: g980-g987. PMID: 16603731, DOI: 10.1152/ajpgi.00336.2005.
- Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat liversLoureiro-Silva MR, Iwakiri Y, Abraldes JG, Haq O, Groszmann RJ. Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers. Journal Of Hepatology 2006, 44: 886-893. PMID: 16545481, DOI: 10.1016/j.jhep.2006.01.032.
- The hyperdynamic circulation of chronic liver diseases: From the patient to the moleculeIwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule. Hepatology 2006, 43: s121-s131. PMID: 16447289, DOI: 10.1002/hep.20993.
- Session 3: Prevention of the Formation of Varices (Pre‐Primary Prophylaxis)Groszann R, Merkel C, Iwakiri Y, Shah V, Shneider B, Zoli M, Berzigotti A, Vorobioff J, Morabito A. Session 3: Prevention of the Formation of Varices (Pre‐Primary Prophylaxis). 2006, 103-151. DOI: 10.1002/9780470988831.ch5.
- Akt1/protein kinase Bα is critical for ischemic and VEGF-mediated angiogenesisAckah E, Yu J, Zoellner S, Iwakiri Y, Skurk C, Shibata R, Ouchi N, Easton RM, Galasso G, Birnbaum MJ, Walsh K, Sessa WC. Akt1/protein kinase Bα is critical for ischemic and VEGF-mediated angiogenesis. Journal Of Clinical Investigation 2005, 115: 2119-2127. PMID: 16075056, PMCID: PMC1180542, DOI: 10.1172/jci24726.
- Targeting of Endothelial Nitric-oxide Synthase to the Cytoplasmic Face of the Golgi Complex or Plasma Membrane Regulates Akt- Versus Calcium-dependent Mechanisms for Nitric Oxide Release*Fulton D, Babbitt R, Zoellner S, Fontana J, Acevedo L, McCabe TJ, Iwakiri Y, Sessa WC. Targeting of Endothelial Nitric-oxide Synthase to the Cytoplasmic Face of the Golgi Complex or Plasma Membrane Regulates Akt- Versus Calcium-dependent Mechanisms for Nitric Oxide Release*. Journal Of Biological Chemistry 2004, 279: 30349-30357. PMID: 15136572, DOI: 10.1074/jbc.m402155200.
- The paradox: vasoconstriction and vasodilationIwakiri Y, Groszmann R. The paradox: vasoconstriction and vasodilation. 2004, 57-67. DOI: 10.1007/978-94-007-1042-9_7.
- A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic ratsLoureiro-Silva MR, Cadelina GW, Iwakiri Y, Groszmann RJ. A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats. Journal Of Hepatology 2003, 39: 940-946. PMID: 14642609, DOI: 10.1016/j.jhep.2003.09.018.
- Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive ratsTsai MH, Iwakiri Y, Cadelina G, Sessa WC, Groszmann RJ. Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Gastroenterology 2003, 125: 1452-1461. PMID: 14598261, DOI: 10.1016/j.gastro.2003.07.014.
- Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in miceGratton J, Lin MI, Yu J, Weiss ED, Jiang ZL, Fairchild TA, Iwakiri Y, Groszmann R, Claffey KP, Cheng Y, Sessa WC. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell 2003, 4: 31-39. PMID: 12892711, DOI: 10.1016/s1535-6108(03)00168-5.
- Neuronal nitric oxide synthase(NNOS) is upregulated in superior mesenteric arteries in portal hypertensive ratsKwon S, Iwakiri Y, Groszmann R. Neuronal nitric oxide synthase(NNOS) is upregulated in superior mesenteric arteries in portal hypertensive rats. Journal Of Hepatology 2003, 38: 62-63. DOI: 10.1016/s0168-8278(03)80613-x.
- Mesenteric vasoconstriction is responsible for the initial eNOS upregulation in the superior mesenteric artery of portal hypertensive ratsTsai M, Iwakiri Y, Cadelina G, Sessa W, Groszmann R. Mesenteric vasoconstriction is responsible for the initial eNOS upregulation in the superior mesenteric artery of portal hypertensive rats. Hepatology 2003, 38: 176-177. DOI: 10.1016/s0270-9139(03)80088-5.
- 44 A liver-specific nitric oxide donor improves the intra-hepatic vascular response to increase portal blood flow and methoxamine in cirrhotic ratsLoureiro-Silva M, Cadelina G, Iwakiri Y, Groszmann R. 44 A liver-specific nitric oxide donor improves the intra-hepatic vascular response to increase portal blood flow and methoxamine in cirrhotic rats. Hepatology 2003, 38: 176. DOI: 10.1016/s0270-9139(03)80087-3.
- Suppression of cyclooxygenase-2 and inducible nitric oxide synthase expression by conjugated linoleic acid in murine macrophages.Iwakiri Y, Sampson DA, Allen KG. Suppression of cyclooxygenase-2 and inducible nitric oxide synthase expression by conjugated linoleic acid in murine macrophages. Prostaglandins, Leukotrienes, And Essential Fatty Acids 2002, 67: 435-43. PMID: 12468265, DOI: 10.1054/plef.2002.0454.
- Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertensionIwakiri Y, Cadelina G, Sessa WC, Groszmann RJ. Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. AJP Gastrointestinal And Liver Physiology 2002, 283: g1074-g1081. PMID: 12381520, DOI: 10.1152/ajpgi.00145.2002.
- Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertensionIwakiri Y, Tsai MH, McCabe TJ, Gratton JP, Fulton D, Groszmann RJ, Sessa WC. Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension. AJP Heart And Circulatory Physiology 2002, 282: h2084-h2090. PMID: 12003815, DOI: 10.1152/ajpheart.00675.2001.
- The phosphorylation of endothelial nitric oxide synthase by Akt increases nitric oxide production in early portal hypertensionIwakiri Y, Tsai M, Sessa W, Groszmann R. The phosphorylation of endothelial nitric oxide synthase by Akt increases nitric oxide production in early portal hypertension. Gastroenterology 2001, 120: a9. DOI: 10.1016/s0016-5085(08)80044-3.
- The phosphorylation of endothelial nitric oxide synthase by Akt increases nitric oxide production in early portal hypertensionIWAKIRI Y, TSAI M, SESSA W, GROSZMANN R. The phosphorylation of endothelial nitric oxide synthase by Akt increases nitric oxide production in early portal hypertension. Gastroenterology 2001, 120: a9-a9. DOI: 10.1016/s0016-5085(01)80044-5.
- Effect of red palm olein on bone tissue fatty acid composition and histomorphometric parametersWatkins, B.A., Li, Y., Rogers, L.L., Hoffmann, W.E., Iwakiri, Y., Allen, K.G.D., and Seifert, M.F. Nutrition Research. 2001;21(1-2):199-213.